登录

血液检测制造商Mirvie推出先兆子痫预防工具包

Blood test maker Mirvie debuts preeclampsia prevention toolkit

Fierce Pharma | 2024-05-02 | 翻译由动脉网AI生成,点击反馈

可切换为仅中文


Preeclampsia, a pregnancy complication typically associated with high blood pressure, is estimated to affect around one in every 12 pregnancies and is a leading cause of both maternal and fetal mortality, as well as long-term complications for survivors.According to data cited by the CDC, the condition is responsible for more than 70,000 maternal deaths and 500,000 fetal deaths around the world every year, with Black women disproportionately affected in the U.S.

先兆子痫是一种通常与高血压相关的妊娠并发症,估计每12次妊娠中就有一次会受到影响,是孕产妇和胎儿死亡以及幸存者长期并发症的主要原因。根据疾病预防控制中心(CDC)引用的数据,这种情况每年导致全世界70000多名孕产妇死亡和500000多名胎儿死亡,美国黑人女性的患病率不成比例。

in particular.In the face of those daunting statistics, Mirvie is helping lead the charge to educate people about how preeclampsia can be prevented.The startup—which is currently developing a blood test that would predict a pregnant person’s risk of preeclampsia months before symptoms first arise—threw its support behind the creation of the first clinical care plan targeting preeclampsia prevention and, in honor of May’s Preeclampsia Awareness Month, has adapted that care plan into an educational toolkit that it’s sharing through a newly launched campaign.The “Preeclampsia Prevention is Possible” campaign site, housed on Mirvie’s own website, includes a collection of downloadable resources aimed mainly at helping clinicians better recognize the early signs of the condition and shape their care plans for high-risk patients.

特别是。面对这些令人望而生畏的统计数据,米尔维正在帮助领导这项指控,教育人们如何预防先兆子痫。这家初创公司目前正在开发一种血液检测方法,可以在症状出现前几个月预测孕妇患先兆子痫的风险,它支持创建首个针对先兆子痫预防的临床护理计划,并为纪念五月的先兆子痫意识月,将该护理计划改编成一个教育工具包,并通过新发起的活动分享。Mirvie自己的网站上有一个“子痫前期预防是可能的”活动网站,其中包括一系列可下载的资源,旨在帮助临床医生更好地识别病情的早期迹象,并为高危患者制定护理计划。

It also includes links to the official care plan and to Mirvie’s own research on preeclampsia risk prediction.“Preeclampsia is often viewed as a complication with limited ability to intervene early and lower the risk of developing the condition,” Eleni Tsigas, CEO of the Preeclampsia Foundation, said in a statement.

它还包括与官方护理计划和Mirvie自己关于先兆子痫风险预测的研究的链接。先兆子痫基金会首席执行官Eleni Tsigas在一份声明中表示:“先兆子痫通常被视为一种并发症,早期干预能力有限,降低发生这种疾病的风险。”。

“However, all year long, and especially during Preeclampsia Awareness Month, we’re amplifying the message that we are in an era where we can better predict, prevent, and prevail ov.

“然而,全年,特别是在先兆子痫意识月期间,我们都在放大这样一个信息,即我们正处于一个可以更好地预测、预防和战胜ov的时代。

推荐阅读

Mirvie宣布完成10000人妊娠健康里程碑式研究的注册

businesswire 2023-11-14 19:00

Mirvie成为第一家获得临床实验室改进修正案(CLIA)认证的以RNA为基础的妊娠健康公司

BioSpace 2023-09-27 04:05

2022年H1全球医疗健康产业资本报告

动脉网APP 2022-07-18 09:54

Fierce Pharma

172篇

最近内容 查看更多

葛兰素史克将出售消费者健康子公司Haleon的剩余股份

10 小时前

勃林格殷格翰与Cigna合作推出Humira生物仿制药

2024-05-13

盐野义制药抗病毒药物在全球COVID-19试验中表现不佳

2024-05-13

相关公司查看更多

Mirvie

孕期血液测试平台

立即沟通

产业链接查看更多

所属赛道

IVD
近30天,融资5起